Optus Pharmaceutical Co Ltd

Optus Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 2.62 and cash and equivalents of 9,999,999,850 KRW, which supports its short-term obligations. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet its liabilities without external financing. In terms of profitability, the company's return on equity (ROE) of 6.88% and return on assets (ROA) of 5.94% are in line with the industry's preferred metrics. These figures suggest that the company is generating returns that are comparable to the industry median, indicating a stable and efficient use of equity and assets. The company's revenue is primarily concentrated in its domestic market, with no significant international exposure disclosed. This concentration may limit its growth potential in the face of domestic market fluctuations. The company's business is centered around the manufacture and sale of pharmaceuticals, with a focus on ophthalmic preparations. Looking at the growth trajectory, the company's revenue is expected to remain stable in the current fiscal year, with no significant growth or decline projected. The company's capital expenditure is negative, indicating a reduction in investment in physical assets, which may affect its long-term growth potential. The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.01 suggests a conservative capital structure, reducing the risk of financial distress. Recent events, including the company's financial performance and market conditions, have not indicated any significant changes in the company's operations or strategic direction. The company's last actual EPS was 894.00 KRW, reflecting its earnings performance.